A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer R. Milroy' on behalf of the West
Summary Proliferation of drug resistant tumour following chemotherapy is the principal cause of treatment failure in small cell lung cancer (SCLC) . Verapamil has been shown to partially restore drug sensitivity in tumour cells rendered resistant in vitro. The results of the first large-scale randomised study of a resistance modifying drug given in conjunction with chemotherapy in cancer patients are reported.
Two hundred and twenty-six patients have been entered. All patients received four cycles of cyclophosphamide (750 mg m-2), doxorubicin (40 mg m-2) and vincristine (1.4 mg m-2) on Day 1 and etoposide (75 mg m -2) on Days 1, 2 and 3, repeated at 21 day intervals. Those patients randomised to the verapamil arm received oral verapamil 120 mg qid for 5 days with each course of chemotherapy. Similar numbers of cycles of protocol treatment were given in both arms with over 75% of patients completing all four cycles.
There were no significant differences in general toxicities between the two arms, except for more severe alopecia in the verapamil treatment group (P = 0.045). There was no significant difference in cardiovascular or haematological toxicity, although the median nadir white cell count after Cycle 1 chemotherapy was lower in the verapamil arm (P = 0.065) and there were significantly more dose reductions after Cycle 1 in the verapamil arm (P = 0.03 1). No statistically significant differences in response (P = 0.582) or survival (P = 0.290) data were seen.
The absence of a significant improvement in response or survival using verapamil may relate to the low blood levels of verapamil seen in the clinic (0.8 gM), in contrast to those known to be maximally active in vitro (>6 pM) or to the presence of other cellular mechanisms by which drug resistance develops.
The emergence of drug resistant tumour following chemothertkpy is the principal cause of treatment failure in small cell lung cancer (SCLC) . Verapamil has been shown to partially restore the drug sensitivity of tumour cells rendered resistant in vitro by chronic exposure to cytotoxic drugs (Tsuruo et al., 1982) . Such cells demonstrate a pattern of cross-resistance to a specific group of cytotoxic drugs (anthracyclines, vinca alkaloids and podophyllotoxins) and are known to contain a membrane energy-dependent cytotoxic drug efflux pump (P-glycoprotein) which is thought to confer drug resistance. The activity of verapamil in such multidrug resistant (MDR) tumour cells relates to inactivation of the P-glycoprotein pump. This effect is known to be dose dependent (Plumb et al., 1990) .
There have been few clinical studies to examine the activity of resistance modifying drugs but pilot clinical studies have shown some responses in pre-treated patients given various verapamil schedules in addition to further chemotherapy (Dalton et al., 1989; Presant et al., 1986) . In these studies the dose limiting toxicity was cardiac (Benson III et al., 1985; Ozols et al., 1987; Presant et al., 1986) . To date only one non-randomised study (Figueredo et al., 1990) has suggested survival benefit from the addition of resistance modifier. Thus, the majority of trials of resistance modulators have concentrated on patients with advanced disease due to resistant tumours following intensive prior chemotherapy. However even at presentation a proportion of resistant tumour cells are probably present and may be susceptible to modulation. This hypothesis has subsequently been borne out by the detection of P-glycoprotein positive cells in untreated tumours in other tumour types (Goldstein et al., 1989 (Cole et al., 1981) .
Statistical methods
The study was stratified for disease extent. The randomisation list was constructed using random permuted blocks of length 6. Comparisons of pretreatment characteristics and survival were based on all randomised eligible patients. All other comparisons used randomised eligible patients who started protocol treatment (see patient demography, Table I 
Results
Recruitment to this study is complete and a total of 226 patients have been entered. Six patients were found to be ineligible soon after randomisation. Reasons for ineligibility included patient refusal (1), death (1), hypotension (1), already on beta blocker (1), already on verapamil (1) and given verapamil in error (1).
In terms of disease extent, performance status, and the prognostic indicators described by Souhami et al. (1985) no significant differences were found between the two arms of the study (Table I) , and similar numbers of cycles of protocol treatment were given in the verapamil and control arms (P = 0.918). The majority of dose reductions were on account of haematological toxicity. There were a similar number of patients who stopped chemotherapy after two courses in both treatment arms. There were a similar number of deaths (nine in verapamil group, ten in control arm) during treatment. The reasons for discontinuing chemotherapy and the causes of death during treatment were similar in each treatment arm.
The worst toxicity during any one patient's treatment was recorded. There were no statistically significant differences in general toxicities between the two arms, except for more severe alopecia in the verapamil treatment group (P = 0.045) (Table II) . Constipation and tiredness (both side-effects of verapamil) were not documented. There was no significant difference in haematological toxicity between the two treatment arms throughout the study. Lowest median nadir blood count values occurred after Cycle 1 in both arms of the study. Haemoglobin (verapamil) 12.5 g dl-', haemoglobin (control) 12.4 g dl-', P = 0.557; white cell count (verapamil) 1.6, white cell count (control) 2.0; P=0.065; platelets (verapamil) 165, platelets (control) 179, P = 0.646. There were significantly more dose reductions after Course 1 in the verapamil treatment arm. Dose reductions occurred after course 1 in 21.4% of patients in the verapamil arm and in 10.2% of patients in the control arm (P = 0.031). Over all cycles there was no significant difference in the incidence of dose reduction in the verapamil (29.9%) and control (19.6%) arms of the study (P = 0.082).
Response data for all the 192 evaluable patients and for the patients divided according to disease extent in each treatment arm are shown in Table III . No statistically significant differences in overall response were seen. A total of 22 patients were unevaluable for response (six did not start on protocol treatment, three did not have response assessed and 13 died before 12 weeks assessment).
Survival curves for the patients, divided according to disease extent at presentation and according to treatment group (verapamil or control) are shown in Figure 1 . As expected, patients with extensive disease show a worse survival pattern. The analysis of the survival curves (based on 220 of the 226 patients) in terms of median survival and death rate is shown in Table IV . This confirms that there is no significant difference in survival between the verapamil treatment and the control arms for the group as a whole (P = 0.290). Also listed in Table IV are the causes of death. There were no significant differences between the verapamil and control arms. The majority of patients have died of tumour progression.
Median verapamil concentration for the 18 patients studied was 387 ng ml-l (0.85 JLM) with a wide inter-patient variation, range = 10-789 ng ml-' and also significant intrapatient variation. Median norverapamil concentration was 350ng ml-' (0.77Mm), range This is the first large-scale randomised study to examine the feasibility and effects, in terms of toxicity, response and survival, of adding a resistance modifier to combination cytotoxic chemotherapy. There has been one published study of resistance naodulation (using verapamil and tamoxifen) in small cell lung cancer which showed that the initial response rate was quite high for this group of patients (complete 24%, overall 58%). Median survival was 46 weeks which compared favourably with historic controls (Figueredo et al., 1990) . A group from Sydney, Australia, are also conducting a randomised study of verapamil given in addition to chemotherapy in small cell lung cancer and the study remains in progress (Bell, 1990) . ( 7) 6.9% ( 5) ED 0.0% (0) 8.3% (2) All 7.3% ( 7) 7.3% ( 7) Progressive LD 8.2% ( 6) 9.7% ( 7) Disease ED 13.0% ( 3) 20.8% ( 5) All 9.4% ( 9) 12.5% (12) Estimated difference in percentage of overall (CR + PR) responders (Verapamil-Control) = 3.1%b 95% c.i. for above difference = - As P-glycoprotein has been shown to be present in normal tissues (Fojo et al., 1987; Thiebault et al., 1987) (Fine et al., 1987; Yalowich et al., 1985) and pilot clinical studies (Benson III et al., 1985; Dalton et al., 1989; Miller et al., 1988; Ozols et al., 1987; Presant et al., 1986) indicate that no enhancement resulting from modifier is likely to occur, in keeping with the observation that P-glycoprotein is not normally expressed at high levels in bone marrow (Sugawara et al., 1988) .
However it has previously been reported that verapamil can increase plasma levels of doxorubicin and reduce doxorubicin clearance (Kerr et al., 1986) . Thus a pharmacokinetic effect might explain the increased alopecia and lower nadir white cell counts after the first course of chemotherapy in the patients in this study treated with verapamil. In this regard the greater incidence of dose reductions after the first course of chemotherapy in the verapamil arm patients is interesting. This presumably related to the lower nadir white cell counts after Course 1, and may account for the lower total cumulative dose of cyclophosphamide noted in the verapamil arm (median 2.5 gm in verapamil arm cf. median 2.7 gm in control arm; P = 0.106).
There was no evidence of increased cardiovascular toxicity caused by verapamil in this study and this presumably related to the relatively low oral dose, with consequently low plasma verapamil levels as previously documented by Kerr et al. (1986) . The levels achieved in patients in that study are well below those optimally active in vitro (over 3000 ng ml-l, 6.6,UM). However similar levels of norverapamil were also achieved and, at least in vitro, verapamil and norverapamil have been shown to have an additive effect in terms of resistance modulation (Merry et al., 1989) . Thus total levels of active modifier achieved in the clinic (1.6 JlM) are at least approaching concentrations known to be active in vitro.
There were no statistically significant differences in response in the two arms of the study (Table III) . There was no statistically significant difference in survival noted between the treatment (verapamil) and control arms in this study. Although the majority (75%) of patients had limited disease, only 29% fell into Souhami's good prognosis category (Souhami et al., 1985) . Thus the median survival of only 45-48 weeks in the limited disease patients in this study is not unexpected. In patients with extensive disease the difference in median survival between the verapamil arm (32 weeks) and the control arm (23 weeks) was more favourable than for patients with limited disease but did not achieve statistical significance.
Thus, in terms of response and survival, overall results in both treatment arms are similar, even though there were more dose reductions in the verapamil treated patients after the first course of chemotherapy. Verapamil may therefore have had some effect and it is possible that with higher plasma levels one might anticipate greater resistance modifying activity particularly as we have demonstrated a dose response effect in vitro (Plumb et al., 1990) . Such an approach is however limited by cardiovascular toxicity (Ozols et al., 1987) . It is known that the L-isomer of verapamil is about ten times more effective as a calcium antagonist than the D-isomer (Ferry et al., 1985) . However the two isomers are equipotent blockers of the fast inward current (Newrath et al., 1981) . Since the effects of verapamil on drug resistance do not appear to relate to calcium antagonism (Ramu et al., 1984) it is conceivable that the D-isomer alone would be a more suitable agent to use clinically in view of the potential, though yet undemonstrated, reduction in cardiovascular sideeffects compared to the racemic mixture. Moreover the Dstereoisomer has been shown to be equally active in terms of resistance modification in SCLC in vitro (Plumb et al., 1990) . Thus use of D-verapamil alone might be a useful approach in future clinical studies of resistance modulation. However, recent work using human tumour biopsies and cell lines now suggests that the P-glycoprotein-mediated (MDR) mechanism of resistance is unlikely to be the major factor in the drug resistance seen in small cell lung cancer (Lai et al., 1989) . Despite this, resistance modulation with verapamil in small cell lung cancer cell lines can still occur (Cole et al., 1989) , raising the possibility of an alternative mechanism of action for this particular modulating agent (Plumb et al., 1989) .
The failure to achieve a more substantial effect in this study may relate to the low blood levels of verapamil seen in the clinic or to the presence of other cellular mechanisms by which drug resistance develops. Further studies of resistance modulation in small cell lung cancer should perhaps employ a combination of agents, especially those where effective concentrations can be more easily achieved in the clinic. Such studies should be based on careful analysis of the mechanisms by which modulation occurs in vitro.
